Mouse Heart Tissue Lysate (0 day old mouse)
Product Code: LEI-M1135
Product Group: Cell and Tissue Lysates and Immunoblots
Supplier: Leinco Technologies
| Code | Size | Price |
|---|
| LEI-M1135-0.1mg | 0.1 mg | £250.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Regulatory Status: RUO
Shipping:
2-8°C
Storage:
This lysate should be aliquoted in working amounts and may be stored for up to one month at 2-8°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. For longer term storage freeze working aliquots at -20 to -70°C.
Further Information
Concentration:
2.0 mg/ml
Format:
The lysate was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.
Formulation:
The lysate was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.
Related Products
| Product Name | Product Code | Supplier | Recombinant Mouse IL-13 Rα2 | LEI-I-567 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Human IL-13 Rα2 | LEI-I-608 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human IL-13 Rα2 (Clone 83834) | LEI-I-688 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse IL-13 Rα2 | LEI-I-723 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||